14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
NOMA vs ABCL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over NOMA (NOMA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). NOMA carries a Unified Composite Score of 49.5/100 (HOLD) at $1.10 (N/M Forward P/E, -164.5% operating margin), whereas ABCL carries 58.6/100 (HOLD) at $10.47 (27.6x Forward P/E, -298.0% operating margin).
Growth vs. Quality Trade-Off: ABCL earns the overall head-to-head edge with a stronger Unified Composite Score (58.6/100 HOLD vs. NOMA 49.5/100 HOLD) and 2.30β · 85% Vol risk profile, whereas NOMA leads top-line expansion (+122.9% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: NOMA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile ABCL is in a Breakdown options structure phase (RSI 38.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NOMA vs ABCL. Trailing 12-month operating profitability (NOMA -164.5% vs ABCL -298.0%) and valuation multiples (NOMA N/M vs ABCL 27.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.6B market capitalization and -298.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ NOMA vs ABCL Key Questions & Quantitative Answers
As of Nov 19, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over NOMA (NOMA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). NOMA carries a Unified Composite Score of 49.5/100 (HOLD) at $1.10 (N/M Forward P/E, -164.5% operating margin), whereas ABCL carries 58.6/100 (HOLD) at $10.47 (27.6x Forward P/E, -298.0% operating margin). Growth vs. Quality Trade-Off: ABCL earns the overall head-to-head edge with a stronger Unified Composite Score (58.6/100 HOLD vs. NOMA 49.5/100 HOLD) and 2.30β · 85% Vol risk profile, whereas NOMA leads top-line expansion (+122.9% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: NOMA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile ABCL is in a Breakdown options structure phase (RSI 38.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABCL leads the Growth & Scale pillar: NOMA posts +122.9% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (71.4% gross margin, -164.5% operating margin), compared with ABCL at +18.8% YoY revenue growth and +45.9% YoY earnings growth on $68M TTM revenue (N/A gross margin, -298.0% operating margin). On trailing 12-month operating scale, NOMA generates $2.0M in USD-normalized revenue versus $68M for ABCL. In operating R&D and SG&A reinvestment, NOMA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABCL.
ABCL screens cheaper on headline valuation multiples. NOMA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 11.4x EV/Revenue (unreported cash flow margin), whereas ABCL trades at 27.6x Forward P/E, 27.6x Trailing P/E, N/M PEG, and 52.6x EV/Revenue (-48.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NOMA (-40.7% ROE) versus ABCL (-14.6% ROE) capital efficiency.
In options market volatility and institutional positioning, NOMA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (-0.45β · 156% Vol realized risk). By comparison, ABCL carries 80.5% implied volatility (24th %ile, Compressed (<25th %ile)), a 0.25x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 85% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.